Erythropoiesis - Injury and Recovery

红细胞生成 - 损伤和恢复

基本信息

  • 批准号:
    8249097
  • 负责人:
  • 金额:
    $ 4.72万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-04-01 至 2014-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): We synthesize and release more than 2 million red blood cells per second from our bone marrow to maintain circulating steady-state levels. This massive output of the erythropoietic system makes it a process that is essential for normal physiological function but also one that is exquisitely sensitive to direct injury such as radiation. Radiation injury provides a unique model for study of erythroid lineage injury, recovery, and regulation mechanisms and allows for a more thorough understanding of erythropoiesis as a dynamic process. The overall aim of this proposal is to better understand the mechanisms of injury and recovery of the erythroid lineage following xenotoxic exposure as modeled by sublethal radiation. Preliminary data obtained through traditional colony assays in combination with a novel multispectral imaging flow cytometry (MIFC) analysis indicate that erythroid progenitors and precursors are severely depleted at 48 hours post 4 Grey irradiation followed by a rapid increase beginning at 5 days post- irradiation. Aim 1 studies will further define the time course of differential radiosensitivity and recovery of erythroid progenitor and precursor populations as well as explore potential apoptotic mechanisms underlying erythroid loss following sublethal radiation injury. Interestingly, preliminary findings suggest that late-stage erythroid progenitors (CFU-E) may recover independent of more immature (BFU-E) progenitors. Based on these data, late-stage erythroid progenitors are hypothesized to proliferate in a modified stress erythropoiesis response that is responsible for the wave of erythroid recovery post-radiation. Therefore, Aim 2 will investigate the role of endogenous compounds important in the traditional stress erythroid response, such as erythropoietin (EPO), stem cell factor (SCF), and glucocorticoids, and their respective signaling pathways on the stimulation and subsequent proliferation of CFU-E cells during the recovery of the erythroid lineage from radiation. Finally, Aim 3 will combine proposed mechanisms underlying injury in Aim 1 and recovery in Aim 2 by determining if exogenous administration of cytokines such as EPO and SCF can reduce injury and enhance recovery of the erythroid lineage. Overall, these experiments will provide a more thorough understanding of normal hematopoiesis by investigating both its underlying sensitivity to radiation and the mechanisms of its recovery response following injury. These studies will ultimately lead to new treatments to protect and mitigate the hematopoietic system from clastogenic agents such as radiation and chemotherapy.
描述(由申请人提供):我们每秒从骨髓中合成和释放超过200万个红细胞,以维持循环稳态水平。红细胞生成系统的这种大量输出使其成为正常生理功能所必需的过程,但也是对辐射等直接损伤非常敏感的过程。辐射损伤为研究红系细胞损伤、恢复和调控机制提供了一个独特的模型,并使我们能够更全面地了解红细胞生成作为一个动态过程。这项建议的总体目标是更好地了解损伤和恢复的机制后,异种毒性暴露的红系亚致死辐射模拟。通过传统的集落测定结合新的多光谱成像流式细胞术(MIFC)分析获得的初步数据表明,红系祖细胞和前体细胞在4Gy照射后48小时严重耗尽,随后在照射后5天开始快速增加。目的1研究将进一步确定红系祖细胞和前体细胞群体的差异放射敏感性和恢复的时间过程,以及探索亚致死辐射损伤后红系损失的潜在凋亡机制。有趣的是,初步研究结果表明,晚期红系祖细胞(CFU-E)可以独立于更不成熟的(BFU-E)祖细胞恢复。基于这些数据,假设晚期红系祖细胞在修饰的应激红细胞生成反应中增殖,该反应负责辐射后红系恢复波。因此,目标2将研究在传统的应激红细胞反应中重要的内源性化合物的作用,如促红细胞生成素(EPO),干细胞因子(SCF)和糖皮质激素,以及它们各自的信号通路对CFU-E细胞的刺激和随后的增殖在红细胞系从辐射中恢复期间。最后,目标3将联合收割机结合目标1中提出的损伤和目标2中提出的恢复的潜在机制,通过确定外源性给予细胞因子如EPO和SCF是否可以减少损伤和增强红系细胞系的恢复。 总的来说,这些实验将提供一个更彻底的了解正常的造血,通过调查其潜在的敏感性辐射和其恢复后的反应损伤的机制。这些研究最终将产生新的治疗方法,以保护和减轻造血系统免受放射和化疗等致染色体断裂剂的影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Scott Alan Peslak其他文献

Scott Alan Peslak的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Scott Alan Peslak', 18)}}的其他基金

Cellular Signaling Pathways in the Regulation of Fetal Hemoglobin for Treatment of Sickle Cell Disease
调节胎儿血红蛋白治疗镰状细胞病的细胞信号通路
  • 批准号:
    10592428
  • 财政年份:
    2021
  • 资助金额:
    $ 4.72万
  • 项目类别:
Cellular Signaling Pathways in the Regulation of Fetal Hemoglobin for Treatment of Sickle Cell Disease
调节胎儿血红蛋白治疗镰状细胞病的细胞信号通路
  • 批准号:
    10424557
  • 财政年份:
    2021
  • 资助金额:
    $ 4.72万
  • 项目类别:
Cellular Signaling Pathways in the Regulation of Fetal Hemoglobin for Treatment of Sickle Cell Disease
调节胎儿血红蛋白治疗镰状细胞病的细胞信号通路
  • 批准号:
    10282012
  • 财政年份:
    2021
  • 资助金额:
    $ 4.72万
  • 项目类别:
Erythropoiesis - Injury and Recovery
红细胞生成 - 损伤和恢复
  • 批准号:
    8448705
  • 财政年份:
    2010
  • 资助金额:
    $ 4.72万
  • 项目类别:
Erythropoiesis - Injury and Recovery
红细胞生成 - 损伤和恢复
  • 批准号:
    7800091
  • 财政年份:
    2010
  • 资助金额:
    $ 4.72万
  • 项目类别:
Erythropoiesis - Injury and Recovery
红细胞生成 - 损伤和恢复
  • 批准号:
    8050106
  • 财政年份:
    2010
  • 资助金额:
    $ 4.72万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 4.72万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 4.72万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 4.72万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 4.72万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 4.72万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 4.72万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 4.72万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 4.72万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 4.72万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 4.72万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了